24/7 Market News Snapshot 28 July, 2025 – Stereotaxis, Inc. Common Stock (NYSE:STXS)

July 28, 2025

DENVER, Colo., 28 July, 2025 (www.247marketnews.com) – (NYSE:STXS) are discussed in this article.
Stereotaxis, Inc. (STXS) is witnessing a robust surge in pre-market trading, with current shares priced at $2.461, reflecting a notable increase of 9.38% from the previous close of $2.250. The trading volume has reached 1.10 million shares, indicating heightened investor interest and activity. This upward trend suggests that the stock may have surpassed its recent resistance levels, signaling potential for continued growth. Investors are advised to closely monitor technical indicators such as Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) for signs of overbought conditions while keeping an eye on key resistance and support levels.

In tandem with this positive market performance, Stereotaxis has announced a significant achievement in the medical technology field, receiving FDA 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. This state-of-the-art device is recognized as the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter. It represents a substantial advancement in the treatment of complex arrhythmias, enhancing the accuracy and efficiency of cardiac ablation procedures.

The MAGiC Sweep catheter is designed with 20 electrodes, allowing for rapid and intricate electroanatomical mapping of heart chambers. Its integration with Stereotaxis’ robotic systems facilitates precise navigation to challenging anatomical areas, with its atraumatic design prioritizing patient safety and ensuring anatomically accurate results. Key opinion leaders in electrophysiology, like Dr. Roderick Tung, have noted that this innovation will significantly improve the understanding and treatment of arrhythmias, while Dr. Daniel Cooper emphasized its potential to create detailed mappings that are essential for effective ablation therapies.

David Fischel, Chairman and CEO of Stereotaxis, underscored the importance of this FDA clearance, framing it as a pivotal moment in the company’s commitment to advancing robotic technologies within the electrophysiology domain and beyond. The introduction of MAGiC Sweep is anticipated to transform patient care and redefine industry standards in cardiac health solutions.

Related news for (STXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.